Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 2.54%.

  • Sangamo Therapeutics' Return on Capital Employed fell 1600.0% to 2.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.54%, marking a year-over-year decrease of 1600.0%. This contributed to the annual value of 1.19% for FY2024, which is 3200.0% down from last year.
  • According to the latest figures from Q3 2025, Sangamo Therapeutics' Return on Capital Employed is 2.54%, which was down 1600.0% from 1.42% recorded in Q2 2025.
  • Sangamo Therapeutics' 5-year Return on Capital Employed high stood at 0.17% for Q1 2021, and its period low was 3.57% during Q2 2024.
  • Over the past 5 years, Sangamo Therapeutics' median Return on Capital Employed value was 0.66% (recorded in 2023), while the average stood at 1.22%.
  • Per our database at Business Quant, Sangamo Therapeutics' Return on Capital Employed tumbled by -29200bps in 2024 and then surged by 21500bps in 2025.
  • Sangamo Therapeutics' Return on Capital Employed (Quarter) stood at 0.3% in 2021, then tumbled by -46bps to 0.43% in 2022, then crashed by -339bps to 1.89% in 2023, then increased by 9bps to 1.71% in 2024, then plummeted by -48bps to 2.54% in 2025.
  • Its Return on Capital Employed was 2.54% in Q3 2025, compared to 1.42% in Q2 2025 and 1.85% in Q1 2025.